Skip to main content
. 2015 May 11;125(6):2473–2483. doi: 10.1172/JCI74159

Figure 6. Contribution of MAPK signaling in SNAI1 expression.

Figure 6

hBMECs were treated with either DMSO vehicle control or a specific MAPK pathway inhibitor. U0126 had the greatest effect on inhibition of GBS-induced SNAI1 expression (A). Treatment of hBMECs with the TLR2 agonist P3C resulted in a dose-dependent increase in SNAI1 expression (B). Treatment of hBMECs with extracts from Δiag or HY106 Δiag resulted in significantly lower SNAI1 expression levels (C). Experiments were performed at least 3 times in triplicate; error bars represent the SEM of at least 3 biological replicates. One-way ANOVA was used to determine significance. *P < 0.05; **P < 0.01; ***P < 0.001.